Oncology

Events

Partner Content

Welcome to the 2nd Tumor Myeloid-Directed Therapies Summit

Identify, Validate, & Clinically Develop Novel Targets to Modulate Myeloid Cells & Overcome Solid Tumor Barriers

News

NHS grants fast-track access to Takeda's lung cancer drug Ex...

Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks.

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

BMS buys into Volastra's cancer expertise with $1.1bn allian...

Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery platform based on chromosomal instability (CIN), a c

News

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development.

News

Merck trial of Keytruda, Lynparza combo in prostate cancer f...

Merck & Co's two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously treated metastatic castration-res

News

Illumina debuts its multi-gene test for cancer in Europe

Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treat

Welcome to the 2nd Tumor Myeloid-Directed Therapies Summit

NHS grants fast-track access to Takeda's lung cancer drug Ex...

BMS buys into Volastra's cancer expertise with $1.1bn allian...

Belgium's Precirix raises €80m to fund radiopharma aspiratio...

Merck trial of Keytruda, Lynparza combo in prostate cancer f...

Illumina debuts its multi-gene test for cancer in Europe

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks